Onyx Biotec Limited (NSE:ONYX)
India · Delayed Price · Currency is INR 32.00
0.00 (0.00%)
At close: Jan 22, 2026
Onyx Biotec Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 663.87 | 619.51 | 537.49 | 394.82 | 448.61 |
Other Revenue | -0 | - | - | 0.1 | - |
| 663.87 | 619.51 | 537.49 | 394.92 | 448.61 | |
Revenue Growth (YoY) | 10.63% | 15.26% | 36.10% | -11.97% | - |
Cost of Revenue | 476.24 | 400.97 | 367.28 | 221.33 | 279.1 |
Gross Profit | 187.63 | 218.55 | 170.21 | 173.59 | 169.51 |
Selling, General & Admin | 86.69 | 86.63 | 59.57 | 105.03 | 86.56 |
Other Operating Expenses | 44.91 | 28.21 | 26.96 | 23.1 | 25.69 |
Operating Expenses | 162.33 | 145.32 | 105.21 | 143.05 | 126.72 |
Operating Income | 25.29 | 73.23 | 65.01 | 30.54 | 42.79 |
Interest Expense | -11.81 | -19.93 | -21.07 | -5.65 | -5.15 |
Interest & Investment Income | 1.73 | 1.73 | 0.75 | 0.65 | 0.1 |
Currency Exchange Gain (Loss) | - | - | - | -0.01 | -0 |
Other Non Operating Income (Expenses) | -7.28 | 0.21 | 0.21 | 0.01 | 0.26 |
EBT Excluding Unusual Items | 7.93 | 55.24 | 44.9 | 25.54 | 38 |
Gain (Loss) on Sale of Assets | 9.54 | 9.54 | - | -0.07 | -0.05 |
Pretax Income | 17.47 | 64.78 | 44.9 | 25.47 | 37.95 |
Income Tax Expense | 6.79 | 15.24 | 8.55 | 7.02 | 4.42 |
Net Income | 10.68 | 49.54 | 36.35 | 18.45 | 33.53 |
Net Income to Common | 10.68 | 49.54 | 36.35 | 18.45 | 33.53 |
Net Income Growth | -75.82% | 36.31% | 97.04% | -44.98% | - |
Shares Outstanding (Basic) | 16 | 15 | 12 | 12 | 12 |
Shares Outstanding (Diluted) | 16 | 15 | 12 | 12 | 12 |
Shares Change (YoY) | 29.63% | 25.51% | 1.13% | - | - |
EPS (Basic) | 0.65 | 3.31 | 3.05 | 1.56 | 2.84 |
EPS (Diluted) | 0.65 | 3.31 | 3.05 | 1.56 | 2.84 |
EPS Growth | -81.34% | 8.60% | 95.20% | -45.07% | - |
Free Cash Flow | -49.81 | 3.62 | -17.07 | -165.01 | -53 |
Free Cash Flow Per Share | -3.02 | 0.24 | -1.43 | -13.98 | -4.49 |
Gross Margin | 28.26% | 35.28% | 31.67% | 43.95% | 37.79% |
Operating Margin | 3.81% | 11.82% | 12.09% | 7.73% | 9.54% |
Profit Margin | 1.61% | 8.00% | 6.76% | 4.67% | 7.47% |
Free Cash Flow Margin | -7.50% | 0.58% | -3.17% | -41.78% | -11.82% |
EBITDA | 56.03 | 103.7 | 83.68 | 45.45 | 57.27 |
EBITDA Margin | 8.44% | 16.74% | 15.57% | 11.51% | 12.77% |
D&A For EBITDA | 30.73 | 30.47 | 18.67 | 14.91 | 14.48 |
EBIT | 25.29 | 73.23 | 65.01 | 30.54 | 42.79 |
EBIT Margin | 3.81% | 11.82% | 12.09% | 7.73% | 9.54% |
Effective Tax Rate | 38.88% | 23.52% | 19.05% | 27.57% | 11.66% |
Revenue as Reported | 668.05 | 631.19 | 538.74 | 396.17 | 449.81 |
Advertising Expenses | - | 0.06 | 0.06 | 0.09 | 0.03 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.